LP-10 (Oral Rinse)

Oral Graft Versus Host Disease

Proprietary Asset

Proprietary Asset

Proprietary Asset

Pre-clinical

Pre-
clinical

Pre-clinical

IND-Enabling

IND-Enabling

IND-Enabling

Phase 1

Phase
1

Phase 1

Phase 2

Phase
2

Phase 2

Phase 3

Phase
3

Phase 3

LP-10 (Oral Rinse)

Oral graft versus host disease

LP-10 (Oral Rinse)

Oral graft versus host disease

LP-10 (Oral Rinse)

Oral graft versus host disease

About Pipeline

LP-10 is an oral rinse formulation intended for the treatment of oral Graft-versus-Host Disease (GvHD), a rare and serious disease.

GvHD is a major cause of morbidity and mortality with chronic GvHD being the leading cause of nonmalignant fatality post hematopoietic cell transplantation (HCT).

Lipella has been granted FDA Orphan Drug Designation for LP-10 in the treatment of GvHD and received IND approval for its Phase 2a clinical trial in March 2024.

  • Lipella Pipeline

  • LP-410 | Oral Graft Versus Host Disease

  • Lipella Pipeline

  • LP-410 | Oral Graft Versus Host Disease

  • Lipella Pipeline

  • Lipella Pipeline

  • LP-410 | Oral Graft Versus Host Disease

  • Lipella Pipeline

  • LP-410 | Oral Graft Versus Host Disease

  • Lipella Pipeline